SCHEMBL406255

SCHEMBL406255

Brc1ccc2[nH]c3cnc(Br)cc3c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 1/20 0.62
GABRA1 P14867 5/20 0.50
GABRG2 P18507 5/20 0.50
GABRB3 P28472 5/20 0.50
GABRA5 P31644 5/20 0.50
GABRA2 P47869 5/20 0.50
GABRP O00591 4/20 0.50
GABRD O14764 4/20 0.50
GABRB1 P18505 4/20 0.50
GABRA3 P34903 4/20 0.50
GABRB2 P47870 4/20 0.50
GABRA4 P48169 4/20 0.50
GABRE P78334 4/20 0.50
GABRA6 Q16445 4/20 0.50
GABRG1 Q8N1C3 4/20 0.50
GABRG3 Q99928 4/20 0.50
GABRQ Q9UN88 4/20 0.50
AR P10275 1/20 0.44
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28526733 0.86 GABRP (0.43) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL14689472 0.82 CHUK (0.58) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL28024979 0.82 GABRA1 (0.68) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL29366993 0.82 CHUK (0.64) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL38602 0.82 CHUK (0.64) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL1984445 0.81 GABRP (0.64) GABRA1GABRG2GABRB3GABRA5GABRA2
SCHEMBL14689627 0.80 GABRA1 (0.67) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL28288154 0.80 CHUK (0.62) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL1980977 0.78 ALDH1A1 (0.66) CHUKGABRA1GABRG2GABRB3GABRA5
SCHEMBL14689765 0.78 CHUK (0.54) CHUKGABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 US disclosed
US-10172827-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-08 US disclosed
US-10172827-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-08 US disclosed
EP-2385829-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2018-08-01 EP disclosed
EP-2385829-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2018-08-01 EP disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 US disclosed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP disclosed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US disclosed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US disclosed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US disclosed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US disclosed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO disclosed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172827-B2 Pro-neurogenic compounds DCX, GAP43, BDNF CHUK 1636/4885GABRA1 741/4885GABRG2 591/4885
US-20180127367-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX CHUK 1180/4885GABRA1 1539/4885GABRG2 1270/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF CHUK 1636/4885GABRA1 741/4885GABRG2 591/4885
US-10183011-B2 Anti-depression compounds BDNF, DCX, GAP43 CHUK 807/4885GABRA1 1382/4885GABRG2 1165/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF CHUK 1584/4885GABRA1 681/4885GABRG2 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.